Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vir Biotechnology's enterprise value is MXN19,871 Mil.
Vir Biotechnology's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was MXN-4,941 Mil. Therefore, Vir Biotechnology's EV-to-EBITDA for today is -4.02.
The historical rank and industry rank for Vir Biotechnology's EV-to-EBITDA or its related term are showing as below:
MEX:VIR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -31.17 Med: -0.83 Max: 11.79
Current: -4.35
During the past 9 years, the highest EV-to-EBITDA of Vir Biotechnology was 11.79. The lowest was -31.17. And the median was -0.83.
MEX:VIR's EV-to-EBITDA is ranked worse than 100% of 401
companies
in the Biotechnology industry
Industry Median: 13.6
vs MEX:VIR: -4.35
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Vir Biotechnology (MEX:VIR) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vir Biotechnology's PE Ratio (TTM) for today is calculated as:
Vir Biotechnology's share price for today is MXN170.00.
Vir Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-34.159.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Vir Biotechnology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:VIR vs AVBP, XNCR, SEPN: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Vir Biotechnology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vir Biotechnology EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vir Biotechnology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vir Biotechnology's EV-to-EBITDA falls into.
Vir Biotechnology's current Enterprise Value is MXN19,871 Mil.
Vir Biotechnology's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-4,941 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vir Biotechnology (MEX:VIR) has a EV-to-EBITDA of -4.02 as of Aug. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vir Biotechnology. According to the industry distribution chart, Vir Biotechnology ranks #999999 out of 401 companies in the Biotechnology industry.
Is Vir Biotechnology's EV-to-EBITDA too high?
Vir Biotechnology's current EV-to-EBITDA is -4.02. Based on the distribution chart, Vir Biotechnology ranks #999999 out of 401 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vir Biotechnology has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Vir Biotechnology's EV-to-EBITDA compare to AVBP and XNCR?
According to the Biotechnology industry distribution chart, Vir Biotechnology ranks #999999 out of 401 companies for EV-to-EBITDA. This places Vir Biotechnology in the lower half of its industry. The industry median EV-to-EBITDA is 13.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.60, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vir Biotechnology. For the Biotechnology industry, the median EV-to-EBITDA is 13.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vir Biotechnology's current EV-to-EBITDA is -4.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vir Biotechnology stock overvalued right now?
Vir Biotechnology (MEX:VIR) has a current EV-to-EBITDA of -4.02. The stock's GF Value™ is MXN755.16, compared to a current price of MXN170.00 — trading 77.5% below its estimated fair value. The current EV-to-EBITDA is -4.02. Vir Biotechnology's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Vir Biotechnology (MEX:VIR), the current EV-to-EBITDA is -4.02 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vir Biotechnology (MEX:VIR) Overvalued in 2026?
Based on GuruFocus' analysis, Vir Biotechnology stock appears to be undervalued.
The current stock price of MXN170.00 is trading 77.5% below its estimated GF Value™ of MXN755.16.
Key valuation signals for MEX:VIR:
EV-to-EBITDA: -4.02
GF Value™: MXN755.16 vs. price of MXN170.00 (77.5% below fair value)
No single metric tells the full story. See the MEX:VIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
52GF Score
Get the complete analysis for MEX:VIR
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:VIR has been successfully added to your 
